台湾疾控中心向那些对MRNA疫苗有不良反应的人提供200 000支Novavax JN.1COVID疫苗。 Taiwan CDC to offer 200,000 Novavax JN.1 COVID vaccines for those who had adverse reactions to mRNA vaccines.

台湾疾控中心将从2022年1月1日起提供200 000剂Novavax JN.1 COVID-19疫苗,作为那些对MRNA疫苗产生不良反应的人的蛋白质替代疫苗。 The Taiwan CDC will offer 200,000 doses of the Novavax JN.1 COVID-19 vaccine starting January 1, 2022, as a protein-based alternative for those who had adverse reactions to mRNA vaccines. 该疫苗针对JN.1次变量,12岁及12岁以上的人可以使用。 This vaccine targets the JN.1 subvariant and is available to individuals aged 12 and above. 疾控中心在购买的550万剂疫苗中,已经注射了170万剂现代1号疫苗。 The CDC has already administered 1.7 million doses of Moderna's JN.1 vaccine out of 5.5 million purchased. 他们敦促未接种疫苗的人,特别是有慢性病的65岁以上的人接种疫苗,以防止严重症状。 They urge unvaccinated people, especially those over 65 with chronic illnesses, to get vaccinated to prevent severe symptoms.